Clinical Trials Browser

Lymphoma × pembrolizumab × 30 days × Clear all

NCT07302347 2026-04-17

MK-3475-G21

Phase 1/2 Recruiting

DermatologicLymphoid

Lymphoma, Neoplasms, Carcinoma, Merkel Cell

NCT03983668 2026-03-30

CMP-001 for Relapsed and Refractory Lymphoma

Phase 1/2 Terminated

14 enrolled 11 charts

Lymphoma